Dr Chris Behrenbruch’s ASX Longtail was a very insightful, humorous and to the point blog. He certainly didn’t hold back on several companies including Starpharma. I tip my hat to his scientific entrepreneurship and business acumen for founding TLX and building the company up to $3B value. They also just announced they are listing in the USA.
Out of respect for Chris I have requested the post be removed, even though his burning assessment of Starpharma is already in the public domain on other Hotcopper threads from previous years.
Of note, I went back and had a look at Starpharma’s ASX release regarding DEP Herceptin in 2015 and guess what?
‘We are very excited by these latest results for our targeted DEP™ conjugates and feedback from commercial parties on this new data has been very positive indeed. Discussions are now underway with a number of pharmaceutical companies…’
Meanwhile, 8 years later …
Ring a bell?
SPL Price at posting:
17.5¢ Sentiment: Sell Disclosure: Not Held
